ONO 41483

Subscribe to Selected New Research on ONO 41483

7 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: inhibits platelet aggregation; structure given in first source; RN given refers to (3aS-(2E,3aalpha,4alpha(1E,3R*),5beta,6aalpha))-isomer

Also Known As:

15-cyclopentyl-omega-pentanor-5(E)-carbacyclin; ONO 41483, 3aS-(3aalpha,4alpha(1E,3R*),5beta,6aalpha)-isomer; ONO-41483; OP 41483; ataprost; Pentanoic acid, 5-(4-(3-cyclopentyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2(1H)-pentalenylidene)-, (3aS-(2E,3aalpha,4alpha(1E,3R*),5beta,6aalpha))-

Bio-Agent Context: Research Results

Related Diseases

1.	Hypothermia 11/01/1989 - "The study suggests that OP-41483 is one of the useful agents to maintain coronary circulation and myocardial metabolism under simple deep hypothermia." Get all the results and reference details, order at left...
2.	Ischemia 05/01/1993 - "The best protective effect was seen when 1,000 ng/kg/min OP-41483 was administered before and after the ischemia" 11/01/1988 - "Experimentally, 45 isolated perfused newborn rabbit hearts (age, 0-2 days) underwent 2 hours of global ischemia at 15 degrees C with a single dose of GIK cardioplegic solution and were subsequently assigned to three groups: Group 1 hearts (n = 15) were infused with basic GIK cardioplegic solution alone (no added calcium, but measured at 0.1-0.2 mM/l); Group 2 hearts (n = 15) received GIK cardioplegic solution with calcium (1.2 mM); and Group 3 hearts (n = 15) received GIK cardioplegic solution with calcium and a PGI2 analogue (OP-41483, 300 micrograms/l)" Get all the results and reference details, order at left...
3.	Peripheral Vascular Diseases (Peripheral Vascular Disease) 05/01/1992 - "These results indicate that OP-41483.alpha-CD has antiplatelet and cutaneous blood flow improving activities that are greater than its hypotensive effect and may be of therapeutic potential in peripheral vascular diseases." Get all the results and reference details, order at left...
4.	Thrombosis (Thrombus) 01/01/1990 - "3) In the electrically induced thrombosis model of guinea pig mesenteric artery, OP-41483 (300-1000 ng/kg/min, i.v.-infusion) and OP-41483 alpha-CD (1.0-3.0 mg/kg, p.o.) inhibited thrombus formation, but heparin (1.0-10 U/kg/min, i.v.-infusion) did not" 01/01/1990 - "4) In the rabbit extracorporeal circulation thrombosis model, OP-41483 (100 and 300 ng/kg/min, i.v.-infusion) inhibited thrombus formation in the extracorporeal shunt and prevented the decrease in platelet count, hematocrit and fibrinogen level in circulating blood" Get all the results and reference details, order at left...
5.	Spasm (Spasms) 09/01/1982 - "In addition, bolus intravenous doses (3 to 10 micrograms/kg) of ONO 41483 reversed vasopressin-induced ECG changes in the monkey, suggesting an ability of the compound to relieve coronary spasm." Get all the results and reference details, order at left...
9 Diseases and 7 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Vasopressins (Vasopressin)
2.	Epoprostenol (Prostacyclin)
3.	Heparin (Liquaemin)
4.	Fibrinogen (Factor I)
5.	Ergotamine (Ergotamine Tartrate)
6.	Epinephrine (Adrenaline)
7.	Cardioplegic Solutions
8.	Calcium
9.	Alprostadil (Muse)
9 Drugs and Important Bio-Agents and 4 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Extracorporeal Circulation
1 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>